Increased alveolar concentrations of exhaled nitric oxide (NO) are associated with lung affection in systemic sclerosis (SSc) Source: Eur Respir J 2005; 26: Suppl. 49, 543s Year: 2005
Differential assessment of airway inflammation in chronic obstructive pulmonary disease (COPD) by measurements of exhaled nitric oxide (NO) derived from peripheral vs. central airways Source: Eur Respir J 2003; 22: Suppl. 45, 279s Year: 2003
Can fractional exhaled nitric oxide be useful to differentiate asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) from COPD-only Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020
Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH) Source: Eur Respir J 2001; 18: Suppl. 33, 83s Year: 2001
Measurement of gas transfer components using nitric oxide in post pulmonary endartectomy (PEA) chronic thromboembolic hypertension (CTEPH) patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function Source: Eur Respir J 2001; 17: 934-938 Year: 2001
Postural change in lung capillary blood volume is less in pulmonary hypertension (PH) compared to healthy controls Source: International Congress 2015 – Lung function: effects on method, machine and disease on the measurement Year: 2015
Increased inflammation in peripheral airways of patients with systemic sclerosis, measured by fractional nitric oxide Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008
Is Fractional exhaled nitric oxide (FeNO) test reliable in the differentiation of chronic obstructive pulmonary disease (COPD) and ACOS (asthma-COPD overlap syndrome)? Source: International Congress 2017 – Lung function testing in different patient categories Year: 2017
Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Atrial natriuretic peptide plasma concentration (ANP) and pulmonary hemodynamics (HEMO) after acute nitric oxide inhalation (NO) in patients with connective tissue disease and pulmonary artery hypertension (CTDPH) Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005
Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH) Source: Eur Respir J 2003; 22: Suppl. 45, 270s Year: 2003
The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH) vs idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009
Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments Source: Eur Respir J 2009; 34: 117-124 Year: 2009
Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008
Increased exhaled nitric oxide precedes lung fibrosis in a murine model of systemic sclerosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012
Pulsed inhaled nitric oxide (iNO) improves exercise tolerance and shortness of breath (SOB) in severe COPD subjects with pulmonary hypertension (PH) Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018
Pulmonary artery pressure (PAP) reduction by systemic and inhaled S-nitroso-N-acetyl-penicillamine (SNAP) in an isolated rabbit lung model of acute lung injury Source: Eur Respir J 2002; 20: Suppl. 38, 37s Year: 2002
Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008
Pulmonary artery pressure (PAP) is reduced by inhaled sodium nitroprusside (SNP) in an isolated lung model of pulmonary hypertension: comparison with systemic application Source: Eur Respir J 2002; 20: Suppl. 38, 4s Year: 2002